Coronary microembolization reduced infarct size compared to controls (18% vs 33%, P<0.05), but this delayed protection was abolished by TNF-alpha antibodies.
Does TNF-alpha mediate progressive contractile dysfunction and delayed protection against infarction following coronary microembolization in anesthetized pigs?
In a porcine model of coronary microembolization, TNF-alpha is responsible for both progressive contractile dysfunction and delayed protection against myocardial infarction.
Absolute Event Rate: 18% vs 33%
p-value: p=<0.05
In patients with unstable angina, plaque rupture and coronary microembolization (ME) can precede complete coronary artery occlusion and impending infarction. ME-induced microinfarcts initiate an inflammatory reaction with increased tumor necrosis factor-alpha (TNF-alpha) expression, resulting in progressive contractile dysfunction. However, TNF-alpha is not only a negative inotrope but can also protect the myocardium against infarction. In anesthetized pigs, we studied whether ME protects against infarction when TNF-alpha expression is increased. ME (group1; n=7) was induced by intracoronary infusion of microspheres (42 microm; 3000 per mL/min inflow). Controls (group 2; n=8) received saline. Groups 3 and 4 (n=4 each) were pretreated with ovine TNF-alpha antibodies (25 mg/kg body weight) 30 minutes before ME or placebo, respectively. Ischemia (90 minutes) was induced 6 hours after ME when TNF-alpha was increased (66+/-21 pg/g wet weight; mean+/-SEM) or after placebo (TNF-alpha, 21+/-10 pg/g; P<0.05). Infarct size (percentage area at risk) was determined after 2 hours of reperfusion (triphenyl tetrazolium chloride staining). ME decreased systolic wall thickening progressively over 6 hours (group 1 versus group 2, 65+/-4% versus 90+/-1%; percentage of baseline; P<0.05). TNF-alpha antibodies attenuated the progressive decrease in systolic wall thickening following ME (group 3, 77+/-5% of baseline; P<0.05 versus group 1) with no effect in controls (group 4; 90+/-8% of baseline). With ME, infarct size was decreased to 18+/-4% versus 33+/-4% in group 2 (P<0.05). The infarct size reduction was abolished by TNF-alpha antibodies (group 3 versus group 4, 29+/-3% versus 35+/-5%). In ME, TNF-alpha is responsible for both progressive contractile dysfunction and delayed protection against infarction.
Skyschally et al. (Fri,) conducted a other in Coronary microembolization (n=23). Coronary microembolization vs. Saline was evaluated on Infarct size (percentage area at risk) (p=<0.05). Coronary microembolization reduced infarct size compared to controls (18% vs 33%, P<0.05), but this delayed protection was abolished by TNF-alpha antibodies.